Skip to content

Jennifer L. Taylor-Cousar, MD, MSCS

Make an Appointment
Jennifer L. Taylor-Cousar

 
Jennifer L. Taylor-Cousar, MD, is a pediatric and adult pulmonologist at National Jewish Health. Dr. Taylor-Cousar sees pediatric and adult pulmonary patients.



Special Interests


Research Interests

Cystic Fibrosis, clinical research, clinical trial design, sexual and reproductive health

Education


Education

1998
Duke University Medical Center (Durham, NC), MD
1993
Stanford University (Stanford, CA), BA, Human Biology
2015
University of Colorado, Aurora, CO, Master of Science, Clinical Science

Residency

1998 - 2002
Duke University Medical Center, Internal Medicine and Pediatrics

Fellowship

2002 - 2006
Duke University Medical Center, Adult and Pediatric Pulmonary Medicine

Awards & Recognition


2023: Distinguished Achievement Award, American Thoracic Society, New York, NY
2022: CF Trailblazer Award, Emily’s Entourage, Merion Station, PA
2022: William J. Martin II Distinguished Achievement Award, American Thoracic Society Public Advisory Roundtable, New York, NY
2020: American Society for Clinical Investigation, Elected Member
2018: ATS Fellow, Inaugural Class, American Thoracic Society, New York, NY
2017: Founder's Award, United States Adult Cystic Fibrosis Association, Indianapolis, IN
2016: Physician of the Year, Colorado Society for Respiratory Care, Denver, CO
2015: Science Transforming Life Award, National Jewish Health, Denver, CO
2014: Viola Vestal Coulter Research Fellow Award
2009: Cystic Fibrosis Research Institute Professional of the Year Award
2009: Selected participant, AAMC Early Career in Medicine Early Career Women Faculty Professional Development Seminar
2008: Clinical Trials Center New Investigator of the Year Award
2006: Duke University Pulmonary Fellowship Scientific Achievement Award
2005: 2nd Place, Fellows’ Clinical Research Presentations, Respiratory Disease Young Investigators Forum
2003: Cystic Fibrosis Foundation Clinical Fellowship

Board Certification


11/2008: ABP, Subspecialty in Pediatric Pulmonary
10/2006: ABIM, Subspecialty in Pulmonary Disease
8/2004: American Board of Internal Medicine
8/2002: American Board of Pediatrics

Professional Memberships


Member, American Thoracic Society
European Cystic Fibrosis Society
European Respiratory Society

Publications


Heijerman HGM, * McKone EF*, Downey DG, Braeckel E,Rowe SM, Tullis E. Mall M, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL*, and McCoy K* on behalf of the VX17-445-103 Trial Group. Efficacy and safety of the elexacaftor/tezacaftor/ivacaftor combination regimen in people with cystic fibrosis homozygous for theF508delmutation: a double-blind, randomised, phase 3 trial.*equal contributions Lancet. 2019 Oct 30. pii: S0140-6736(19)32597-8. doi: 10.1016/S0140-6736(19)32597-8. PMID: 31679946

Middleton PG*, Mall MA*, Drevinek P, Lands LC, McKone EF, Polineni D, Ramsey BW,Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM** and Jain R** for the VX17-445-102 Study Group. Elexacaftor-Tezacaftor-Ivacaftor for CF with a Single Phe508del Mutation.New Eng J Med. 2019. Epub ahead of print

Downey DG andTaylor-Cousar JL. Challenges and opportunities in the development of future CFTR modulator options for people with CFPMID: 31672556

Keating D, Sass L Burr L, Daines C, Rowe S, Savage J, Simard C, Xuan F, Van Goor F, Robertson S, McKee C, Waltz D, Marigowda G, and Taylor-Cousar JL (corresponding author). VX-445 in Combination with Tezacaftor-Ivacaftor in Phe508del Homozygous and Heterozygous Patients with Cystic Fibrosis. N Engl J Med 2018; 379:1612-1620 DOI: 10.1056/NEJMoa1807120 PMID: 30334692

Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone E, Plant B, Paris D, Ramsey B, Taylor-Cousar JL, Tullis E, Uluer A, McKee CM, Robertson S, Shilling RA, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Rowe SM. Triple Combination of VX-659/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and One or Two F508del-CFTR Alleles. N Engl J Med 2018 Oct 25;379(17):1599-1611. doi: 10.1056/NEJMoa1807119 PMID: 303334693

Hospital Affiliations


  • Children's Hospital Colorado
  • St. Joseph Hospital - Denver
  • University of Colorado Hospital

Academic Affiliations


2009-Present: Professor, Department of Medicine, Division of Pulmonary Sciences and Critical Care Medicine and the Department of Pediatrics, Pulmonary Division, University of Colorado Denver.

Teaching & Professional Positions


2019-present
Professor (tenured)
Co-Director (2015-)/CF TDN Director (2017-), Adult CF Program
Departments of Internal Medicine and Pediatrics
Pulmonary Divisions
National Jewish Health
Denver, CO
                                                                       
2019-present
Professor
Departments of Internal Medicine and Pediatrics
Pulmonary Divisions
University of Colorado
Aurora, CO
 
2014-present
Medical Staff
Pulmonary Medicine
Saint Joseph Hospital
Denver, CO
              
2014-2019
Associate Professor (tenured, 2019)
Co-Director (2015-)/CF TDN Director (2017-), Adult CF Program
Departments of Internal Medicine and Pediatrics
Pulmonary Divisions
National Jewish Health
Denver, CO
         
2014-2019
Associate Professor
Departments of Internal Medicine and Pediatrics
Pulmonary Divisions
University of Colorado
Aurora, CO    
 
2009-present              
Medical Staff
Department of Pulmonology
Children’s Hospital Colorado
Aurora, CO
 
2009-2014 
Assistant Professor
Associate Adult CF Program Director (2011-2014)
Departments of Medicine and Pediatrics
Pulmonary Divisions
National Jewish Health
Denver, CO
 
2009-2014
Assistant Professor
Departments of Medicine and Pediatrics
Pulmonary Divisions
University of Colorado
Aurora, CO
           
2006-2009
Assistant Professor
Adult Cystic Fibrosis Program Director, Associate CF Center Director
Departments of Internal Medicine and Pediatrics
Pulmonary Divisions
University of New Mexico
Albuquerque, NM

Conflicts of Interest


National Jewish Health physicians and scientists may collaborate with pharmaceutical or other industries to develop medical and scientific breakthroughs or to provide education on trends in quality medical practice and outcomes to physicians and health professionals around the country. National Jewish Health maintains a strict conflict of interest policy to ensure that all potential conflicts are clearly visible and that management plans are put in place in order to further innovation and education while ensuring the protection of our patients and the integrity of our research. National Jewish Health publicly discloses any payment to our physicians or scientists. View this faculty member’s industry relationships and collaborations.